Olympia Pharmaceuticals, a FDA-registered 503B outsourcing facility, is marketing a range of injectable wellness and weight management products, including popular GLP-1 receptor agonists and various research peptides. The company highlights its ability to bypass traditional supply shortages by offering compounded versions of these high-demand medications for office use, alongside other injectables like NAD+ and proprietary blends for weight loss.